Tiiu Noobel
From:
[email protected]
Sent: kolmapäev, 15. juuli 2020 15:13
To:
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected]; Marten Kokk;
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected]
Cc:
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected]; ges-1-
[email protected];
[email protected];
[email protected];
[email protected];
[email protected]; Esindus EL juures üldaadress; Tairi
Täht;
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected]; J.-
[email protected];
[email protected];
[email protected];
[email protected]; jml@reper-
portugal.be;
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected].;
[email protected]
Subject: Letter from EU Commissioner Stella Kyriakides to all Ministers of Health on the
Communication ‘ Short term EU Preparedness for COVID -19 outbreaks’
Attachments: Cover letter registered.pdf; Letter registered.pdf
Importance: High
Dear Ambassadors,
Please find attached letter from EU Commissioner Stella Kyriakides to all Ministers of Health. It would be
appreciated if the letter could be transmitted to the respective Minister of Health.
Kind Regards,
1
Christian Cassar
Assistant
European Commission
Cabinet of Commissioner Stella Kyriakides
Health and Food Safety
Rue de la Loi 200, BERL 10/390
B-1049 Brussels/Belgium
Telephone: +32 2 29 88690
Email:
[email protected]
2
Ref. Ares(2020)3740349 - 15/07/2020
European
Commission
STELLA KYRIAKIDES Rue de la Loi, 200
MEMBER OF THE EUROPEAN COMMISSION B-1049 Brussels - Beri 10/380
HEALTH AND FOOD SAFETY
[email protected]
Brussels.
Dear Minister,
Today the Commission adopted its Communication on “Short term EU preparedness for
Covid-19 outbreaksI take the opportunity to thank you for the close cooperation during
these past months and renew my firm commitment to you to work ever more closely together
to prepare for future COVID-19 outbreaks. The current period of relative stabilisation offers
us an opportunity to increase our collective preparedness against the virus. While the EU is
no longer the epicentre of the pandemic, the virus is still very much present.
As during these last months, a coordinated and joint approach, that is informed by science
and respects the EU core values of freedom of movement, respect for individual rights and
solidarity, will be the most effective way to overcome any challenges.
I would like to provide you with an overview of ongoing and planned joint procurements, and
activities financed through the Emergency Support Instrument. Both instruments offer
important opportunities to be better prepared for the months to come, until safe and
efficacious vaccines are available.
It is important to keep in mind that joint procurement is a preparedness tool and procedures
normally take time. Elowever, the Commission took exceptional measures to speed up these
complex processes in the midst of the pandemic.
As you know, in the meantime all 27 EU countries signed the Joint Procurement Agreement
as well as, the UK, the 3 EEA countries (Norway Iceland and Liechtenstein) and Albania,
Bosnia and Herzegovina, Montenegro, Serbia, North Macedonia and Kosovo1,2.
So far, five joint procurement procedures have been launched covering personal protective
equipment, ventilators, laboratory equipment and Intensive Care Unit medicines. All these
4his designation is without prejudice to positions on status, and is in line with UNSCR 1244/1999 and the ICJ Opinion on the Kosovo
declaration of independence.
2 Following the European Council call of 26 March 2020 to open the Joint Procurement Agreement to the Western Balkans, discussions
started with the six partners concerned. Some countries have not yet completed their national approval procedures. Until they notify the
Commission by submitting Annex II, they shall not be taken into account for the purposes of reaching a common accord, qualified majority
or simple majority under the Agreement.
framework contracts provided Member States with access to critical supplies worth up to €
3.3 billion over the course of one year.3
Whereas the volume, price and timing of deliveries ultimately depend on the companies (and
timing of the orders by the countries), joint procurement improves the economies of scale and
supports a more equitable access to the market for all participating authorities. Since mid-
April, the Commission has been informed of seven countries having placed orders for almost
seven million units of personal protective equipment. Orders have also been placed for
ventilators and laboratory equipment. I encourage you to closely monitor the availability of
these essential medical countermeasures and take advantage of the on-going contracts to
prepare for potential increases in demand and avoid a repeat of the shortages in equipment we
experienced earlier this year.
Beyond our joint procurements, via the Emergency Support Instrument, the Commission has
made a purchase of 10 million KN95 masks, which can be distributed to all EU 27 countries
and the UK. Acknowledging the lack of quality of masks of the first delivery, the
Commission has been working to resolve the issue. We have been ensuring quality control
tests in-situ in China and are arranging for further quality control tests upon arrival of the
masks in the EU. The results of these tests will be shared with Member States prior to
distribution. We plan to deliver the first masks in the days to come and hope to finalise this
operation in the beginning of August.
Increase of testing capacity is fundamental in order to control outbreaks and be better
prepared for a second wave. The Red Cross is working to reinforce national capacity and
provide support via mobile equipment to be deployed to places in need.
In parallel to these efforts, and knowing that the real game changer against the pandemic will
be a safe and effective vaccine, last month we launched the EU vaccine strategy4, for which a
significant part of the Emergency Support Instrument funds will be allocated. The
Commission is well advanced in the negotiation of Advanced Purchase Agreements with
several pharmaceutical companies towards ensuring access to large volumes of Covid-19
vaccines as soon as possible. I would like to thank all of you for your commitment to the EU
approach and your experts’ active and constructive participation in this process which will
benefit all of us.
I would also like to take this opportunity to highlight the work of the Commission about
securing access to therapeutics. The European Emergency Support Instrument will finance
actions to generate clinical evidence to support an application for a marketing authorisation
for treatment of COVID-19 patients of repurposed molecules, such as Raloxifene. The use of
COVID-19 convalescent plasma as a treatment for COVID-19 patients will be also supported
via financing of plasmapheresis equipment and training programmes and to that effect, the
National Blood Authorities have already been contacted.
Regarding the therapeutic Remdesivir, as you are aware, the European Commission has
approved the use of this medication to treat severe cases of COVID-19 following the
3 (Adjustments to the ceilings may occur as more contracts are negotiated.)
4 https://ec.europa.eu/commission/presscorner/detail/en/ip 20 1103
recommendation by the European Medicines Agency. At the same time, here too, we are
going to deploy the European Emergency Support Instrument to secure a supply of the
Remdesivir treatment by purchasing up to 30.000 treatment courses during the months of
July, August and September to the EU 27 and the UK. We are also negotiating further EU
access to Remdesivir for October, November and December and for that purpose we are
preparing a joint procurement agreement, for which we are currently collecting the needs and
which all interested Member States can join.
Time is of the essence to ensure that the EU is well prepared to respond to further outbreaks
of COVID-19. Preparedness can save lives and prevent further damage to our economies.
The full weight of the Commission’s and EU Agencies’ support to Member States will be
brought to bear against the challenge posed by the COVID-19 pandemic, and I am confident
that together we can act in a coordinated way to protect our citizens, having learnt the lessons
of the earlier part of this year.
I look forward to tomorrow’s discussion in the EPSCO and I am confident we will find ways
of further strengthening our crisis preparedness and management capacity.
Yours sincerely,
Electronically signed on 15/07/2020 13:45 (UTC+02) in accordance with article 4.2 (Validity of electronic documents) of Commission Decision 2004/563
Tanel Kiik
Sotsiaalminister
Sotsiaalministeerium 15.07.2020
nr 10.1-13/656-1
Austatud härra minister
Edastame Teile Euroopa Komisjoni voliniku Stella Kyriakides’e 15.07.2020 kirja nr
Ares(2020) 3740349 (Commission’s adopted communication on „Short term EU Preparedness
for COVID -19 outbreaks“).
Lugupidamisega
Marten Kokk
Esinduse asejuht Coreper I küsimustes
Lisad: Voliniku kiri 3 lk
Tiiu Noobel +32 2227 4337
[email protected]
Rue Guimard 11/13 1040 Brüssel Tel: +32 2 227 39 10
[email protected] www.eu.mfa.ee/et